Related Experiment Videos
Evaluation of pituitary function in children using growth hormone secretagogues
1Department of Pediatrics, University of South Florida College of Medicine, All Children's Hospital, St. Petersburg, FL 33701, USA.
Insights
A new diagnostic test evaluates pituitary secretory potential in children by comparing responses to growth hormone-releasing hormone (GHRH) and growth hormone-releasing peptides (GHRP). This helps identify the best therapy for slow growth, optimizing treatment outcomes.
Area of Science:
- Pediatric Endocrinology
- Growth Hormone Physiology
- Diagnostic Medicine
Background:
- Assessing pituitary secretory potential is crucial for diagnosing growth disorders in children.
- Current methods may not fully differentiate between pituitary capacity and endogenous secretagogue adequacy.
Purpose of the Study:
- To develop a novel diagnostic test for evaluating pituitary secretory potential.
- To guide the selection of appropriate therapies for children with slow growth.
Main Methods:
- Sequential and combined administration of growth hormone-releasing hormone (GHRH) and growth hormone-releasing peptides (GHRP) or their mimics.
- Comparison of pituitary responses to individual and combined secretagogue stimulation.
Main Results:
- The test differentiates between pituitary secretory capacity and endogenous secretagogue sufficiency.
- It allows for the assessment of functional pituitary elements versus inadequate endogenous complements.
Conclusions:
- The proposed diagnostic scheme accurately assesses endogenous GH secretagogue adequacy and pituitary secretory capacity.
- This approach enables tailored therapeutic selection, including GHRH, GHRP, or recombinant GH.
Abstract:
We have devised a diagnostic test to directly evaluate pituitary secretory potential, and also to identify the most appropriate therapy for slow growing children. The test compares responses to GH releasing hormone (GHRH) and GH releasing peptides or their non-peptidyl mimics (GHRP) administered sequentially and in combination. Since they are functional complements, robust GH secretion in response to GHRH or GHRP could be interpreted as representing adequate endogenous GHRP or GHRH, respectively. Alternatively, assuming that all pituitary cellular and molecular elements for GHRH- and GHRP-mediated GH secretion are functional, a poor response to either GH secretagogue administered individually could represent inadequacy of its endogenous complement. The integrity of functional pituitary elements could be differentiated from inadequate endogenous complement by administering both GH secretagogues simultaneously. Based upon this hypothesis, the proposed pituitary function diagnostic scheme could be used to test for endogenous GH secretagogue adequacy, as well as pituitary secretory capacity. The data resulting from application of these principles would allow appropriate selection of therapeutic entities, ranging from GHRH or GHRP administered separately or in combination, or alternatively, recombinant GH for those patients lacking a pituitary mechanism for GH production and/or secretion.